Xin Lang Cai Jing·2025-09-23 07:24Group 1 - The core viewpoint of the news is that Fosun Pharma's stock has been declining for five consecutive days, with a total drop of 6% during this period, and the current stock price is 30.22 yuan per share, with a market capitalization of 807 billion yuan [1] - Fosun Pharma's main business includes drug manufacturing and research, covering medical devices, medical services, and pharmaceutical distribution and retail. The revenue composition is as follows: oncology and immunomodulation products account for 45.68%, anti-infection products 17.53%, metabolic and digestive system products 13.83%, cardiovascular products 9.80%, raw materials and intermediates 6.43%, central nervous system products 5.21%, and other business revenues 1.52% [1] Group 2 - From the perspective of fund holdings, one fund under the Fortune Fund has heavily invested in Fosun Pharma. The Fortune National Vaccine and Biotechnology ETF (159645) increased its holdings by 12,800 shares in the second quarter, bringing the total to 87,300 shares, which constitutes 11.36% of the fund's net value, making it the largest holding [2] - The Fortune National Vaccine and Biotechnology ETF (159645) has a current scale of 19.2941 million, with a year-to-date return of 14.16% and a one-year return of 31.97%. However, since its inception, it has incurred a loss of 23.65% [2]